Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells $14,902.03 in Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov sold 2,431 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $6.13, for a total transaction of $14,902.03. Following the completion of the sale, the chief executive officer now owns 187,471 shares of the company’s stock, valued at $1,149,197.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Monday, June 3rd, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.76, for a total transaction of $16,433.56.
• On Wednesday, May 1st, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.11, for a total transaction of $22,146.41.
• On Friday, April 5th, Rosty Raykov sold 44,300 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.75, for a total transaction of $476,225.00.
• On Wednesday, April 3rd, Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.78, for a total transaction of $437,495.52.

Fennec Pharmaceuticals Price Performance

Shares of FENC opened at $6.03 on Friday. The company has a quick ratio of 6.72, a current ratio of 6.93 and a debt-to-equity ratio of 9.86. Fennec Pharmaceuticals Inc has a twelve month low of $5.97 and a twelve month high of $11.92. The company has a market capitalization of $164.76 million, a P/E ratio of 201.00 and a beta of 0.29. The firm has a 50 day moving average of $7.34 and a 200 day moving average of $9.19.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its earnings results on Tuesday, May 14th. The company reported $0.41 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.08). Fennec Pharmaceuticals had a negative return on equity of 39.41% and a net margin of 6.33%. The company had revenue of $25.38 million during the quarter, compared to the consensus estimate of $10.46 million. During the same period last year, the firm posted ($0.23) EPS. As a group, equities research analysts anticipate that Fennec Pharmaceuticals Inc will post 0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Eudaimonia Advisors LLC grew its position in Fennec Pharmaceuticals by 90.8% in the 4th quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock worth $367,000 after purchasing an additional 15,556 shares during the period. Jump Financial LLC bought a new stake in Fennec Pharmaceuticals in the 4th quarter worth approximately $158,000. Worth Venture Partners LLC grew its position in shares of Fennec Pharmaceuticals by 52.7% during the 4th quarter. Worth Venture Partners LLC now owns 141,500 shares of the company’s stock valued at $1,588,000 after acquiring an additional 48,864 shares during the period. Russell Investments Group Ltd. grew its position in shares of Fennec Pharmaceuticals by 71,275.0% during the 1st quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company’s stock valued at $381,000 after acquiring an additional 34,212 shares during the period. Finally, Gendell Jeffrey L grew its position in shares of Fennec Pharmaceuticals by 7.1% during the 1st quarter. Gendell Jeffrey L now owns 302,478 shares of the company’s stock valued at $3,364,000 after acquiring an additional 20,000 shares during the period. Institutional investors own 55.51% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on FENC shares. Craig Hallum lowered their target price on shares of Fennec Pharmaceuticals from $20.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, May 15th. Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Fennec Pharmaceuticals in a report on Tuesday, May 14th. Finally, HC Wainwright lowered their target price on shares of Fennec Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, May 15th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.